Articles producció científica> Medicina i Cirurgia

In silico clinical trials for anti-aging therapies

  • Dades identificatives

    Identificador: imarina:5825619
    Autors:
    Menendez JCuyàs EFolguera-Blasco NVerdura SMartin-Castillo BJoven JAlarcón T
    Resum:
    Therapeutic strategies targeting the hallmarks of aging can be broadly grouped into four categories, namely systemic (blood) factors, metabolic manipulation (diet regimens and dietary restriction mimetics), suppression of cellular senescence (senolytics), and cellular reprogramming, which likely have common characteristics and mechanisms of action. In evaluating the potential synergism of combining such strategies, however, we should consider the possibility of constraining trade-off phenotypes such as impairment in wound healing and immune response, tissue dysfunction and tumorigenesis. Moreover, we are rapidly learning that the benefit/risk ratio of aging-targeted interventions largely depends on intra- and inter-individual variations of susceptibility to the healthspan-, resilience-, and/or lifespan-promoting effects of the interventions. Here, we exemplify how computationally-generated proxies of the efficacy of a given lifespan/healthspan-promoting approach can predict the impact of baseline epigenetic heterogeneity on the positive outcomes of ketogenic diet and mTOR inhibition as single or combined anti-aging strategies. We therefore propose that stochastic biomathematical modeling and computational simulation platforms should be developed as in silico strategies to accelerate the performance of clinical trials targeting human aging, and to provide personalized approaches and robust biomarkers of healthy aging at the individual-to-population levels.
  • Altres:

    Autor segons l'article: Menendez J; Cuyàs E; Folguera-Blasco N; Verdura S; Martin-Castillo B; Joven J; Alarcón T
    Departament: Medicina i Cirurgia
    Autor/s de la URV: Joven Maried, Jorge
    Paraules clau: Senolytics Inflammation Cancer Biomathematics Aging
    Resum: Therapeutic strategies targeting the hallmarks of aging can be broadly grouped into four categories, namely systemic (blood) factors, metabolic manipulation (diet regimens and dietary restriction mimetics), suppression of cellular senescence (senolytics), and cellular reprogramming, which likely have common characteristics and mechanisms of action. In evaluating the potential synergism of combining such strategies, however, we should consider the possibility of constraining trade-off phenotypes such as impairment in wound healing and immune response, tissue dysfunction and tumorigenesis. Moreover, we are rapidly learning that the benefit/risk ratio of aging-targeted interventions largely depends on intra- and inter-individual variations of susceptibility to the healthspan-, resilience-, and/or lifespan-promoting effects of the interventions. Here, we exemplify how computationally-generated proxies of the efficacy of a given lifespan/healthspan-promoting approach can predict the impact of baseline epigenetic heterogeneity on the positive outcomes of ketogenic diet and mTOR inhibition as single or combined anti-aging strategies. We therefore propose that stochastic biomathematical modeling and computational simulation platforms should be developed as in silico strategies to accelerate the performance of clinical trials targeting human aging, and to provide personalized approaches and robust biomarkers of healthy aging at the individual-to-population levels.
    Àrees temàtiques: Odontología Nutrição Medicina veterinaria Medicina iii Medicina ii Medicina i Interdisciplinar Geriatrics & gerontology Ciências biológicas ii Ciências biológicas i Cell biology Biotecnología
    ISSN: 19454589
    Adreça de correu electrònic de l'autor: jorge.joven@urv.cat
    Identificador de l'autor: 0000-0003-2749-4541
    Data d'alta del registre: 2024-09-07
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referència a l'article segons font original: Aging-Us. 11 (16): 6591-6601
    Referència de l'ítem segons les normes APA: Menendez J; Cuyàs E; Folguera-Blasco N; Verdura S; Martin-Castillo B; Joven J; Alarcón T (2019). In silico clinical trials for anti-aging therapies. Aging-Us, 11(16), 6591-6601. DOI: 10.18632/aging.102180
    DOI de l'article: 10.18632/aging.102180
    Entitat: Universitat Rovira i Virgili
    Any de publicació de la revista: 2019
    Tipus de publicació: Journal Publications
  • Paraules clau:

    Cell Biology,Geriatrics & Gerontology
    Senolytics
    Inflammation
    Cancer
    Biomathematics
    Aging
    Odontología
    Nutrição
    Medicina veterinaria
    Medicina iii
    Medicina ii
    Medicina i
    Interdisciplinar
    Geriatrics & gerontology
    Ciências biológicas ii
    Ciências biológicas i
    Cell biology
    Biotecnología
  • Documents:

  • Cerca a google

    Search to google scholar